Transcriptional Dysregulation: A Therapeutic Target for Polyglutamine Diseases

E-ISSN： 1875-6158|5|2|119-127

ISSN： 1568-0150

Source： Current Medicinal Chemistry - Central Nervous System Agents, Vol.5, Iss.2, 2005-06, pp. : 119-127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine Diseases

Current Pharmaceutical Biotechnology, Vol. 11, Iss. 2, 2010-02 ,pp. : 188-197

Bentham Science Publishers

Access to resources Recommend Favorite

Peptide-Based Therapeutic Approaches for Treatment of the Polyglutamine Diseases

Current Medicinal Chemistry, Vol. 21, Iss. 23, 2014-08 ,pp. : 2575-2582

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Approaches to Polyglutamine Diseases: Combating Protein Misfolding and Aggregation

Current Pharmaceutical Design, Vol. 12, Iss. 20, 2006-07 ,pp. : 2543-2555

Bentham Science Publishers

Access to resources Recommend Favorite

Conformational Changes and Aggregation of Expanded Polyglutamine Proteins as Therapeutic Targets of the Polyglutamine Diseases: Exposed &bgr;-Sheet Hypothesis

Current Pharmaceutical Design, Vol. 14, Iss. 30, 2008-10 ,pp. : 3267-3279

Bentham Science Publishers

Access to resources Recommend Favorite

HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET

Current Drug Targets, Vol. 17, Iss. 1, 2016-01 ,pp. : 33-45

Bentham Science Publishers

Access to resources Recommend Favorite